Evidence map›Paper›PMID 36434614›Full record

ArticleVirology journal2022

Assessment of antibody responses against SARS-CoV-2 in unvaccinated individuals and vaccinees from Omicron-BA.2 infection in Zhaoqing, Guangdong Province, China.

Huan Zhang, Yushan Jiang, Hanqing Tan, Lirong Zou, Zhonghua Zheng, Yushi Huang, Shujian Lin, Lebin Su, Jianxiang Yu, Xiaoling Deng and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. The regulation of lncRNAs and miRNAs in SARS-CoV-2 infection.Frontiers in cell and developmental biology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Huan Zhang *Guangdong Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.
Yushan Jiang *Biosafety Level-3 Laboratory, School of Public Health, Southern Medical University, 510515, Guangzhou, China.
Hanqing Tan *Microbiological Laboratory, Zhaoqing Center for Disease Control and Prevention, Zhaoqing, China.
Lirong Zou *Guangdong Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.
Zhonghua ZhengGuangdong Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.
Yushi HuangGuangdong Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.
Shujian LinGuangdong Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.
Lebin SuMicrobiological Laboratory, Zhaoqing Center for Disease Control and Prevention, Zhaoqing, China.
Jianxiang YuGuangdong Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.
Xiaoling DengGuangdong Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.
Jianfeng HeGuangdong Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.
Chang LiuMicrobiological Laboratory, Zhaoqing Center for Disease Control and Prevention, Zhaoqing, China. sjkzx_lc@zhaoqing.gov.cn.
Chenguang ShenBiosafety Level-3 Laboratory, School of Public Health, Southern Medical University, 510515, Guangzhou, China. a124965468@smu.edu.cn.
Baisheng LiGuangdong Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China. libsn@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, the majority of the global population has been vaccinated with the COVID-19 vaccine, and characterization studies of antibodies in vivo from Omicron breakthrough infection and naive infection populations are urgently needed to provide pivotal clues about accurate diagnosis, treatment, and next-generation vaccine design against SARS-CoV-2 infection. We showed that after infection with Omicron-BA.2, the antibody levels of specific IgM against the Wuhan strain and specific IgG against Omicron were not significantly elevated within 27 days of onset. Interestingly, in this study, the levels of humoral immunity against Omicron-specific IgM were significantly increased after breakthrough infection, suggesting that the detection of Omicron-specific IgM antibodies can be used as a test criterion of Omicron breakthrough infection. In addition, we observed that serums from unvaccinated individuals and the majority of vaccinated infections possessed only low or no neutralizing activity against Omicron at the onset of Omicron breakthrough infections, and at the later stage of Omicron-BA.2 breakthrough infection, levels of neutralization antibody against the Wuhan and Omicron strains were elevated in infected individuals. The findings of this study provide important clues for the diagnosis of Omicron breakthrough infections, antibody characterization studies and vaccine design against COVID-19.

Indexed as

Antibody FormationCOVID-19Antibodies, ViralCOVID-19 VaccinesHumansImmunoglobulin MSARS-CoV-2Antibodies, ViralCOVID-19 VaccinesImmunoglobulin MAntibody responsesBreakthrough infectionIgMNeutralization antibodyOmicron-BA.2

Identifiers

PMID36434614
PMCPMC9701007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.